RADX Radiopharm Theranostics Ltd


$ 4.55 $ -0.13 (-2.81 %)    

Thursday, 20-Nov-2025 15:55:54 EST
QQQ $ 586.19 $ -14.20 (-2.37 %)
DIA $ 458.32 $ -3.66 (-0.79 %)
SPY $ 653.15 $ -10.10 (-1.52 %)
TLT $ 89.26 $ 0.35 (0.39 %)
GLD $ 374.80 $ -0.11 (-0.03 %)
$ 4.49
$ 4.85
$ 4.39 x 2,600
$ 4.80 x 200
$ 4.65 - $ 5.22
$ 3.50 - $ 50.82
33,701
na
na
$ 0.68
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company fo...

Core News & Articles

Previous comprehensive preclinical proof-of-concept Biodistribution studies of RAD 402 in mouse xenografts showed strong tumour...

Core News & Articles

Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to M...

Core News & Articles

Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceut...

Core News & Articles

Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from s...

Core News & Articles

Financial updateThe following is a summary of the Appendix 4C Cash Flow Report:The year-end closing cash balance was $29.12 mil...

Core News & Articles

- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceu...

Core News & Articles

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, &, ldquo, Radiopharm&, rdquo, or the &, ldquo, Company&, rdquo,...

Core News & Articles

Brookline Capital analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and an...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION